Cure My Disease

Don't miss your cure!

 Log in / Sign up

Large-scale study monitors real-world use of RA drug peficitinib

NCT ID NCT03971253

Recruiting now Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 34 times

Summary

This study is observing 3000 people with rheumatoid arthritis who are starting peficitinib for the first time. Researchers are tracking side effects and how well the drug controls disease activity in real-world settings. The goal is to understand the drug's safety and effectiveness outside of controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site JP00001

    RECRUITING

    Hokkaido, Japan

  • Site JP00002

    RECRUITING

    Aomori, Japan

  • Site JP00003

    RECRUITING

    Numakunai, Japan

  • Site JP00004

    RECRUITING

    Miyagi, Japan

  • Site JP00005

    RECRUITING

    Akita, Japan

  • Site JP00006

    RECRUITING

    Yamagata, Japan

  • Site JP00007

    RECRUITING

    Fukushima, Japan

  • Site JP00008

    RECRUITING

    Ibaraki, Japan

  • Site JP00009

    RECRUITING

    Tochigi, Japan

  • Site JP00010

    RECRUITING

    Gunma, Japan

  • Site JP00011

    RECRUITING

    Saitama, Japan

  • Site JP00012

    RECRUITING

    Chiba, Japan

  • Site JP00013

    RECRUITING

    Tokyo, Japan

  • Site JP00014

    RECRUITING

    Kanagawa, Japan

  • Site JP00015

    RECRUITING

    Niigata, Japan

  • Site JP00016

    RECRUITING

    Toyama, Japan

  • Site JP00017

    RECRUITING

    Ishikawa, Japan

  • Site JP00018

    RECRUITING

    Fukui, Japan

  • Site JP00019

    RECRUITING

    Yamanashi, Japan

  • Site JP00020

    RECRUITING

    Nagano, Japan

  • Site JP00021

    RECRUITING

    Gifu, Japan

  • Site JP00022

    RECRUITING

    Shizuoka, Japan

  • Site JP00023

    RECRUITING

    Aichi, Japan

  • Site JP00024

    RECRUITING

    Mie, Japan

  • Site JP00025

    RECRUITING

    Shiga, Japan

  • Site JP00026

    RECRUITING

    Kyoto, Japan

  • Site JP00027

    RECRUITING

    Osaka, Japan

  • Site JP00028

    RECRUITING

    Hyōgo, Japan

  • Site JP00029

    RECRUITING

    Nara, Japan

  • Site JP00030

    RECRUITING

    Wakayama, Japan

  • Site JP00031

    RECRUITING

    Tottori, Japan

  • Site JP00032

    RECRUITING

    Shimane, Japan

  • Site JP00033

    RECRUITING

    Okayama, Japan

  • Site JP00034

    RECRUITING

    Hiroshima, Japan

  • Site JP00035

    RECRUITING

    Yamaguchi, Japan

  • Site JP00036

    RECRUITING

    Tokushima, Japan

  • Site JP00037

    RECRUITING

    Kagawa, Japan

  • Site JP00038

    RECRUITING

    Ehime, Japan

  • Site JP00039

    RECRUITING

    Kochi, Japan

  • Site JP00040

    RECRUITING

    Fukuoka, Japan

  • Site JP00041

    RECRUITING

    Saga, Japan

  • Site JP00042

    RECRUITING

    Nagasaki, Japan

  • Site JP00043

    RECRUITING

    Kumamoto, Japan

  • Site JP00044

    RECRUITING

    Ōita, Japan

  • Site JP00045

    RECRUITING

    Miyazaki, Japan

  • Site JP00046

    RECRUITING

    Kagoshima, Japan

  • Site JP00047

    RECRUITING

    Okinawa, Japan

Conditions

Explore the condition pages connected to this study.

RHEUMATOID ARTHRITIS (RA)